NeOnc Technologies Holdings Inc
Research NeOnc Technologies Holdings Inc (NTHI) on Bullrun: market cap USD 67.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNTHI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 67.85M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 14.24M
- Free cash flow-USD 4.77M
Valuation Snapshot
latest market cap is USD 67.85M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 39.99K | -USD 62.15M | -USD 20.86M | n/a | -3.2 | USD 58.73K | USD 6.31M | -USD 17.51M |
| FY2024 | USD 83.00K | -USD 11.90M | -USD 4.21M | n/a | -0.69 | USD 64.89K | USD 24.72K | -USD 5.50M |
| FY2023 | USD 70.46K | -USD 14.92M | -USD 1.88M | n/a | -0.8 | USD 31.86K | USD 6.61M | -USD 13.99M |
| FY2022 | USD 20.00K | -USD 3.05M | -USD 881.74K | n/a | -0.16 | USD 633.30K | USD 50.00K | -USD 1.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 67.85M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 157.35M | n/a | n/a | n/a |
About NeOnc Technologies Holdings Inc
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NeOnc Technologies Holdings Inc's market cap?
NeOnc Technologies Holdings Inc's market capitalization is USD 67.85M.
What does NeOnc Technologies Holdings Inc do?
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.